Citations

Clear

3057 citation(s) found for "Cd, Johnson".

TMEM119+ microglia MHC class I restricted antigen presentation impacts CD8 T cell memory, effector status, and blood-brain barrier disruption during neurotropic virus infection
Seady, Marina , Maynes, Mark Andrew, Thelwell, Javonte , Jin, Fang, Hansen, Michael J, Jensen, Hadley E, Witter, Ryann K, Hassani, Asma, Lewis, Cody L, Forston, Michael D. , Johnson, A, Johnson, Aaron , Seady, Marina, Maynes, Mark, Thelwell, Javonte, Jin, Fang, Hansen, Michael, Witter, Ryann, Owens, Carley, Hassani, Asma , Lewis, Cody , Seady, Marina

Mayo Clinic

No container title available | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.08.722741 | PMID 42182166 Get It

Abstract The impact of microglia antigen presentation on CNS infiltrating CD8 T cells responses during neurotropic virus infection has been difficult to define. Using Theiler’s murine encephalomyelitis virus (TMEV) infection of neurons as a model system, our laboratory has previously determined that H-2D b restricted, but not H-2K b restricted CD8 T cells are required for viral clearance, demonstrating the role of discrete MHC class I alleles. To determine the extent microglia antigen presentation impacts brain-infiltrating CD8 T cells, our laboratory generated novel single MHC class I conditional knockout mice in which H-2K b or H-2D b can be specifically deactivated in TMEM119+ microglia with tamoxifen administration. During TMEV infection, conditional knockout of H-2K b in microglia reduced antigen-specific CD8 T cell proliferation in the brain. Meanwhile, mice with deletion of D b in microglia had reduced levels of perforin in antigen-specific CD8 T cells. Furthermore, microglia specific deletion of H-2D b reduced CD8 T cell numbers in the brain and preserved blood-brain barrier (BBB) integrity. Microglial D b restricted antigen presentation was also essential for the reactivation of CD8 tissue resident memory (TRM) cells and BBB integrity during memory recall responses. These findings further our understanding of how brain infiltrating antiviral CD8 T cell responses are impacted by microglia, as well as define how this cellular interaction contributes to BBB disruption during neuroinflammation. These findings also have high significance to our understanding of how microglia impact CD8 TRM cell populations that reside in the brain long after virus infection is cleared. Graphical abstract
Intermittent Hypoxia Training in Heart Failure: A Pilot Study
Morris, Norman, Roberts, Llion, Sharma, Pramod, Foo, Max, O'Connor, Fergus, Hawes, Alice, Johnson, Bruce, Sabapathy, Surendran , Morris, Norman , Roberts, Llion Arwyn , O’Connor, Fergus K.

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2298853 Get It

Introduction/Aim: Heart failure (HF) is a complex clinical syndrome, characterised by reduced exercise capacity (VO 2 peak) and quality of life leading to premature death. The reduction in VO 2 peak is a key prognostic indicator, and improving exercise capacity remains a critical therapeutic target. In athletes, the use of intermittent hypoxia training to improve VO 2 peak and performance is well established. Changes in VO 2 peak are typically accompanied by improved oxygen carrying capacity with increased haemoglobin (Hb) concentration mediated through increased erythropoietin (EPO) production in the kidney. The purpose of this pilot study was to examine the feasibility of using intermittent hypoxia training in individuals with HF, and examine changes in VO 2 peak, EPO and Hb. We hypothesised that intermittent hypoxia training would be feasible, well tolerated, and improve VO 2 peak, EPO production, Hb concentration in HF with reduced ejection fraction (HFrEF). Methods: Ten male participants with stable, optimally managed HFrEF (Age: 73 ± 5 yr; Ejection Fraction: 37 ± 11%) participated in the study. The training stimulus consisted of 12 x 60-minute sessions of intermittent hypoxia over a 2-week period. During each 60-minute session participants received 6 x 5 minutes of pulsed, reduced FIO 2 exposures interspersed with 5 min of normoxia (total of 30 min hypoxic exposure per session). All participants commenced at 18% FIO 2 , which was decreased to 12% by the 3-4th sesion, as tolerated. Throughout each exposure, oxygen saturation (SpO 2 ), heart rate, blood pressure and dyspnoea (modified Borg scale) were monitored every 5 min. Changes in VO 2 peak were measured using a cycle ergometry, cardiopulmonary exercise test. Changes in VO 2 peak, N-terminal pro B-type natriuretic peptide (NT-proBNP), EPO and Hb concentration were measured pre and immediately post intermittent hypoxic training. Results: All participants completed between 10-12 (median n=12) sessions over the 2-week period. Intermittent hypoxia was well-tolerated with no adverse events. The mean SpO 2 during the hypoxic exposure was 88 ± 4%, and median reported dyspnoea 0 (range 0-1). Following 2 weeks of intermittent hypoxic training, there were significant increases in VO 2 peak (mean difference[MD]: +1.18 mL·kg - ¹·min - ¹, 95% CI 0.47 to 1.89, p = 0.010); EPO (MD: +3.33 IU/L, 95% CI 1.35 to 5.32, p = 0.011); with a modest increase in Hb concentration that approached significance (MD: +4.00 g/L, 95% CI 0.51 to 7.49, p = 0.055). NT-proBNP remained unchanged (MD: –107 pg/mL, 95% CI –356 to 142, p = 0.424). Conclusion The results of this pilot study suggest that in clinically stable HFrEF, 2 weeks of intermittent hypoxic training results in a significant improvement in VO 2 peak, accompanied by increases in EPO and potentially levels of Hb. In our participants, this 60-minute pulsed intermittent hypoxic protocol was extremely well tolerated without any adverse effects, and may improve oxygen carrying capacity of the blood in HFrEF. Further research on the mechanisms of adaptation and the translation of the response into different HF phenotypes is warranted. Supported By: The Prince Charles Hospital Foundation Innovation Grant INN202-049 and Griffith University. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Endothelial Cell CD36 ablation attenuates obesity-induced endothelial dysfunction in obesity
Johnson, Erica, Hudgins, Emma, Nguyen, Thanh, Rokka, Sabita, Kashyap, Bhaswati , Halbert, Caitlin, McCarthy, Elizabeth, Tascone, Anthony, Fancher, Ibra, Johnson, Erica J. , Hudgins, Emma Judith , Halbert, Caitlin , McCarthy, Elizabeth , Tascone, Anthony R., Fancher, Ibra S.

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2300315 Get It

Obesity is a complex metabolic disease that is the leading risk factor for cardiovascular disease. In obesity, adipose arteries exhibit robust endothelial dysfunction (ED). A major hallmark of ED is loss in flow induced vasodilation (FIV). Kir2.1 is an inwardly rectifying K+ channel that contributes to FIV through the downstream production of nitric oxide, a potent vasodilator. Work from our group demonstrated that in addition to loss in FIV, endothelial cells (ECs) isolated from obese mice exhibited blunted Kir2.1 currents. Plasma long chain fatty acids (LCFAs) are well established to be elevated in obesity and have been separately shown to inhibit Kir2.1 channels. CD36 is the major fatty acid translocase responsible for the uptake of LCFAs and we therefore aimed to determine if CD36 was contributing to this loss in Kir2.1 function. We previously showed that global CD36 ablation restores endothelium-dependent dilations to flow. These findings prompted us to explore the role of EC CD36 in negatively regulating Kir2.1 function. We performed patch clamp electrophysiology experiments on freshly isolated ECs from the Tie2eCreCD36fl/fl model and determined that EC CD36 ablation restores Kir2.1 currents in obesity. To further explore the established relationship between Kir2.1 and FIV, we performed ex vivo pressure myography experiments to evaluate endothelial dependent dilations to flow. EC CD36 ablation restored responses to flow in arteries from obese mice, an effect that could be blunted by inhibiting Kir2.1 suggesting that CD36 ablation in endothelium rescues the Kir2.1 contribution to FIV. To determine if obesity alters the expression of endothelial CD36, arteries from mice and humans undergoing bariatric surgery were isolated and en face preparations were stained to locate the EC layer and assess CD36 expression. Confocal imaging of en face arteries coupled with flow cytometry on isolated endothelial cells revealed that obesity did not alter the expression of CD36 in endothelium of mesenteric arteries relative to controls in WT mice or humans. As expression did not change, we next probed functionality of CD36 in obese vs. control in mice and humans. Arteries were exposed to a fluorescent fatty acid, BODIPY C-16, at various time points followed by en face preparations and confocal microscopy. As expected, obese vessels exhibited elevated amounts of fatty acid uptake (FAU) at all time points relative to control in mice and humans, suggesting an increase in CD36. To further confirm this change in function, we repeated FAU experiments in the Tie2eCreCD36fl/fl model and found that EC CD36 ablation attenuated FAU in obese vessels compared to both their lean and genotype controls. Taken together, this work suggests that an increase in CD36 function drives impairment of Kir2.1. This work establishes a CD36/Kir2.1 axis worthy of further exploration including understanding how CD36 and LCFAs are impairing Kir2.1 upstream. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program
O'Hagan, Anne, Loriot, Y, Deprince, Kris, Crow, Lauren, Laron, Michal, Adelman, Ron, Sweiti, Hussein , Triantos, Spyros, Triantos, Spyros , O’Hagan, Anne, Siefker-Radtke, Arlene Odelia , Loriot, Yohann , Laron, Michal

Mayo Clinic

The Oncologist | May 12, 2026 | Volume: 31 | Issue: 7 | Pages: No page available

10.1093/oncolo/oyag174 | PMID 42127981 Get It

Abstract Background Fibroblast growth factor receptors inhibitors (FGFRi) are approved treatments for various malignancies. FGFRi-associated retinopathy is a class effect of FGFRi, including erdafitinib, pemigatinib, infigratinib, and rogaratinib. Patients and Methods We summarized FGFRi-associated retinopathy with erdafitinib across 5 clinical studies in patients with metastatic urothelial cancer (mUC pooled studies) and one study in patients with advanced solid tumors (RAGNAR). We also present changes in visual acuity, retinal pigment epithelial elevation, and subretinal fluid in RAGNAR. Results One hundred and three (21.5%) of 479 patients in the mUC pooled studies and 43/314 (13.7%) patients in RAGNAR experienced FGFRi-associated retinopathy. Most FGFRi-associated retinopathy were Grade 1/2 events. Grade 3 FGFRi-associated retinopathy were infrequent (mUC pooled studies, 11/479 [2.3%]; RAGNAR, 3/314 [1.0%]). No Grade 4 events occurred. Most FGFRi-associated retinopathy events (mUC pooled studies, 81/103 [78.6%]; RAGNAR, 30/43 [70.0%]) occurred within 90 days of treatment initiation and were managed with erdafitinib dose interruption (mUC pooled studies, 41/479 [8.6%]; RAGNAR, 23/314 [7.3%]) or reduction (mUC pooled studies, 58/479 [12.1%]; RAGNAR, 21/314 [6.7%]); few required treatment discontinuation (mUC pooled studies, 14/479 [2.9%]; RAGNAR, 3/314 [1.0%]). By the data cutoff, 63.1% (65/103) patients in the mUC pooled studies and 65.1% (28/43) patients in RAGNAR had their FGFRi-associated retinopathy events resolve. Most unresolved FGFRi-associated retinopathy events were persistent Grade 1 events. In RAGNAR, 92.0% of patients had their visual acuity return to baseline and 78.5% of patients had their retinal pigment epithelial elevation resolve. Conclusions FGFRi-associated retinopathy with erdafitinib can be managed with dose reductions, interruptions, or discontinuations. Proactive collaboration between oncologists and ophthalmologists is required to ensure that erdafitinib delivers clinical benefit to patients while managing their potential adverse symptoms of FGFRi-associated retinopathy.
Abnormal amyloid PET usually represents intermediate/high Alzheimer's disease neuropathologic change
Burkett, Brian J. , Wiste, Heather J. , Johnson, D H, Boeve, Bradley F., Kantarci, Kejal, Petersen, Ronald C., Knopman, David S., Vemuri, Prashanthi, Graff‐Radford, Jonathan, Lowe, Val, Cogswell, Petrice M., Pillai, Jay, Schwarz, Christopher G., Murray, Melissa E., Dickson, Dennis W., Jack, Clifford R., Pillai, Jay J. , Burkett, Brian , Pillai, Jay J , Boeve, Bradley F. , Kantarci, Kejal , Petersen, Ronald C. , Knopman, David S. , Vemuri, Prashanthi , Graff‐Radford, Jonathan , Lowe, Val J. , Cogswell, Petrice M. , Schwarz, Christopher G. , Nguyen, Aivi T. , Murray, Melissa E. , Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | May 7, 2026 | Volume: 22 | Issue: 5 | Pages: No page available

10.1002/alz.71449 | PMID 42092343 Get It

Abstract INTRODUCTION Alzheimer's disease neuropathologic change (ADNC) classification identifies not/low and intermediate/high levels of neuropathology. Our goal was to assess how frequently a positive amyloid positron emission tomography (PET) scan indicates not/low ADNC and whether this autopsy finding can occur >10 years after a positive amyloid PET. METHODS Participants with positive amyloid PET scans were categorized by levels of ADNC at autopsy, grouped by time from initial positive amyloid PET to time of death (<5 years, 5 to <10 years, or 10+ years). RESULTS Among those with a positive amyloid PET scan, the majority had intermediate/high ADNC at autopsy (234/259, 90%). In the group with 10+ years between a positive amyloid PET and death ( n = 39) not/low ADNC occurred in 3/39 (8%). DISCUSSION Not/low ADNC is uncommon among those with positive amyloid PET scans. After 10+ years, it is possible but rare for a positive amyloid PET scan to represent an indolent state of neuropathology.
An APOE *4-Informed Genomic Atlas of the X Chromosome in Alzheimer’s Disease
Cook, Noah , Zeng, Youjie , Yang, Chenyu , Jiang, Zhiwen , Wang, Ting‐Chen , Guen, Yann Le , Cody, Karly Alex , Johnson, Matthew, Zhang, Rui, Merritt, Victoria C. , Hauger, Richard L. , Program, the VA Million Veteran, FinnGen, Koran, Mary Ellen, Mormino, Elizabeth C. , Gordon, Brian , DeCasien, Alex, Andrews, Shea J. , Logue, Mark, Greicius, Michael D. , Le Guen, Yann , Cody, Karly A , Koran, Mary Ellen , Gordon, Brian A , Andrews, Shea , Dumitrescu, Logan , Archer, Derek , Seto, Mabel , Pottier, Cyril , Cruchaga, Carlos , Sherva, Richard , Logue, Mark W. , Napolioni, Valerio , Belloy, Michael E , Cook, Noah , Zeng, Youjie , Yang, Chenyu , Zhang, Rui, Merritt, Victoria C. , Hauger, Richard L. , Koran, Mary Ellen I. , Mormino, Elizabeth C. , DeCasien, Alex R. , Dumitrescu, Logan , Archer, Derek B. , Hohman, Timothy J. , Belloy, Michaël E.

Mayo Clinic

No container title available | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.05.26352461 | PMID 42145643 Get It

Abstract The genetic contributions of the X chromosome to Alzheimer’s disease (AD) remain poorly understood yet are expected to importantly shape sex differences in AD. We therefore performed large-scale X-chromosome-wide association studies (N=1,240,451), evaluating differential risk due to sex, APOE *4, and escape from X-chromosome inactivation, finding most X-linked loci appear relevant to female-biased AD etiology. In evaluating genetic pleiotropy with hormonal, lipid, and brain imaging traits, we discovered X-linked AD loci converged on white matter traits, particularly in the anterior corona radiata and splenium of the corpus callosum. Through brain-centric functional genomics analyses, we then nominated candidate causal genes, including 5 that appeared highly robust. Notably, we found the escape gene RBBP7 decreases AD risk in APOE *4 carriers likely through higher expression in excitatory neurons to counter tau-related neurodegeneration. Altogether, we provide an atlas of sex and APOE *4-informed candidate X-linked AD risk loci, genes, and mechanisms that will guide future studies.
Soluble Thrombomodulin Links Viremia and Mortality During COVID‐19: Results From the ACTIV‐4a Trial
Zuchelkowski, Benjamin E. , Inman, Kyle, Nouraie, S Mehdi, Beru, Neeharika, Naqvi, Asma , Qin, Shulin, Yeh, Calvin H., Zhang, Yingze , Shah, Faraaz , Sharma, Lokesh , Zhang, Lianghui , Morris, Alison, Kim, Paul Y., Jacobs, Jana L. , Nouraie, Mehdi , Inman, Kyle W , Nouraie, Seyed Mehdi , Shah, Faraaz A , Zhang, Lianghui , McVerry, Bryan J , Morris, Alison , Neal, Matthew D , Seheult, Jansen N , Kitsios, Georgios D , Mellors, John W , Lawrence, Daniel A , Kim, Paul Y , Jacobs, Jana L , Bain, William G , Zhang, Yingze , Inman, Kyle , Naqvi, Asma , Qin, Shulin , Yeh, Calvin H., Sharma, Lokesh , Dela Cruz, Charles S , Seheult, Jansen N.

Mayo Clinic

Journal of the American Heart Association | May 6, 2026 | Volume: 15 | Issue: 10 | Pages: No page available

10.1161/jaha.125.047693 | PMID 42089155 Get It

Background COVID‐19 and other respiratory viral infections can cause cardiovascular complications. SARS‐CoV‐2 virions are found in the blood, and circulating viral RNA levels are associated with death. We hypothesized that viremia can induce thrombotic endotheliopathy that contributes to death and studied this relationship in patients hospitalized for COVID‐19 and enrolled in the ACTIV‐4a (Accelerating COVID‐19 Therapeutic Interventions and Vaccines) randomized trial of antithrombotic therapy. Methods We quantified SARS‐CoV‐2 nucleocapsid RNA and protein in plasma and measured their associations with clinical outcomes and biomarkers of thromboinflammation and endotheliopathy. We used Cox regression and Fine–Gray competing risk models to analyze survival and thrombosis. We conducted causal mediation analysis to explore whether thrombotic endotheliopathy mediates the relationship between viral RNA and death. Results In 93 patients, SARS‐CoV‐2 RNA and N‐antigen were higher in nonsurvivors. Baseline viral RNA levels were associated with increased 90‐day death (hazard ratio [HR], 1.31 [95% CI, 1.17–1.46]) and thrombosis (HR, 1.35 [95% CI, 1.24–1.47]). Viral RNA more effectively predicted survivorship than N‐antigen levels. Soluble thrombomodulin, a biomarker of thrombotic endotheliopathy, positively correlated with viral RNA levels. Mediation analysis revealed that soluble thrombomodulin accounts for 12.2% (95% CI, 0.1%–32.3%; P =0.048) after adjustment for age and sex of the relationship between viral RNA and the 90‐day mortality rate. Conclusions Elevated plasma SARS‐CoV‐2 RNA levels are associated with death in ACTIV‐4a, which is causally mediated in part by soluble thrombomodulin. We propose that lung–blood viral dissemination is a potential mechanism for cardiovascular complications of respiratory viruses. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04505774.
ABSTRACT NUMBER: ESOC2026A250 MULTIMODALITY IMAGING FOR PATENT FORAMEN OVALE EVALUATION (MAINFRAME)
Knopp, Rachel, Flemming, Kelly, Scharf, Eugene, Keser, Zafer, Prink, Jessica, Johnson, Shari, Reeder, Guy, Brown, R D, Harmsen, William, Khan, Muhib, Flemming, Kelly D. , Scharf, Eugene , Keser, Zafer , Johnson, Shari, Reeder, Guy S.

Mayo Clinic

European Stroke Journal | May 6, 2026 | Volume: 11 | Issue: Supplement_1 | Pages: i135-i136

10.1093/esj/aakag023.225 Get It

Abstract Background and aims Patient foramen ovale (PFO) is a stroke risk factor evaluated using transthoracic echocardiogram (TTE), transesophageal echocardiogram (TEE), transcranial Doppler ultrasound (TCD), and cardiac computed tomography (CCT). TCD is non-invasive, but its diagnostic performance relative to other modalities is unclear. We hypothesized that TCD has high sensitivity but low specificity for PFO detection. Methods We conducted an IRB-approved, single-center retrospective study of patients undergoing TCD for right-to-left shunt (RLS) detection between January 2024 and April 2025. Patients were identified from the Neurosonology Laboratory Quality Database. Records were reviewed for demographics, comorbidities, and TTE, TEE, and CCT findings. Sensitivity, specificity, and positive and negative predictive values were calculated for TCD, TTE, and CCT relative to TEE, the gold standard. The sensitivity and specificity of TCD versus TTE were compared using McNemar test. Results Ninety-two patients were included. Mean age was 52.66 ± 15.78 years, and 51% were female; qualifying events included ischemic stroke or transient ischemic attack. RLS was detected in 53 patients (57.6%) by TCD, 17 (30%) by TTE, 18 (28.5%) by TEE, and 3 (21%) by CCT. TCD demonstrated 94% sensitivity and 53% specificity, (PPV 66%, NPV 89%). TTE showed 50% sensitivity and 82% specificity (PPV: 75%, NPV 61%), while CCT showed 33% sensitivity and 100% specificity (PPV 100%, NPV 33.3%). TCD had significantly higher sensitivity than TTE for RLS detection (p=0.039) with a non-significant difference in specificity (p=0.062), using TEE as the reference. Conclusions TCD has high sensitivity for RLS detection in patients with ischemic stroke or transient ischemic attack. Conflict of interest Rachel Knopp: nothing to disclose; Kelly Flemming: nothing to disclose; Eugene Scharf: nothing to disclose; Zafer Keser: nothing to disclose; Jessica Prink: nothing to disclose; Shari Johnson: nothing to disclose; Guy Reeder: nothing to disclose; Robert Brown: nothing to disclose; William Harmsen: nothing to disclose; Muhib Khan: nothing to disclose Table 1 - belongs to Results
Use of Machine‐Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension
DuBrock, Hilary M. , Tang, Xiaoqin , Doad, Gurinderpal , Lam, Jenny , Cho, Michelle , Murugadoss, Karthik , Doddahonnaiah, Deeksha , Wagner, Tyler E. , DuBrock, Hilary M , Murugadoss, Karthik , Doad, Gurinderpal , Cho, Michelle , Wagner, Tyler E

Mayo Clinic

Pulmonary Circulation | May 6, 2026 | Volume: 16 | Issue: 2 | Pages: No page available

10.1002/pul2.70294 | PMID 42099826 Get It

ABSTRACT Clinical worsening events are increasingly recognized as a meaningful outcome in pulmonary arterial hypertension (PAH). We applied machine‐learning models to real‐world data to identify clinical features that may predict clinical worsening events in PAH. Data were obtained retrospectively from the electronic health records of adults diagnosed with PAH at Mayo Clinic locations (January 2015–December 2019). Machine‐learning LASSO regularized logistic regression models were developed to analyze the association between 100 clinical features and occurrence of clinical worsening events. In total, 455 patients were included (mean age 62.1 years; 59.3% female). Of these, 232 (51.0%) experienced a clinical worsening event after a median (quartile 1, quartile 3) of 10.9 (4.1, 21.4) months. The best‐performing model had an area under the curve of 0.78, sensitivity of 78%, and specificity of 59%. The model identified 11 clinical features associated with clinical worsening events in PAH with a non‐zero coefficient: baseline age, body mass index (BMI), creatinine level, red cell (erythrocyte) distribution width (RDW), mean pulmonary arterial pressure, pulmonary vascular resistance, sodium concentration, and QT interval, along with dyspnea, number of clinic visits, and other forms of heart disease within a 1‐month window before a clinical worsening event. Baseline RDW and BMI, and number of clinic visits within the 1‐month window were statistically significantly associated with clinical worsening events. Our study used machine‐learning models to identify clinical features associated with risk of clinical worsening events in PAH. Automation of risk prediction could lead to earlier therapeutic intervention to optimize patient outcomes.
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE
Bahlis, Nizar J. , Facon, Thierry, San-Miguel, Jesus, Usmani, Saad Z., Dimopoulos, Meletios-Athanasios A., Moreau, Philippe, Manier, Salomon , NS, Raje, Orlowski, Robert Z. , Goldschmidt, H, Hulin, Cyrille, Weisel, K, Leleu, Xavier, Plesner, Torben , Jakubowiak, Andrzej J, Cook, Gordon, Quach, H, Venner, Christopher P., Cavo, M, Ngo, Mai, Bolyard, Kasey, Carson, R, Borgsten, Fredrik, Mateos, María‐Victoria , Kumar, Shaji , Miguel, Jesús F. San , Bahlis, Nizar Jacques , San-Miguel, Jesus , Zweegman, Sonja , Perrot, Aurore , Manier, Salomon , Orlowski, Robert Z. , Goldschmidt, Hartmut , Mohty, Mohamad , Leleu, Xavier , Cook, Gordon , Quach, Hang , Mateos, María-Victoria , Kumar, Shaji K , Facon, Thierry T.F. , Usmani, Saad Z. , Dimopoulos, Meletios A , Moreau, Philippe , Chari, Ajai , Goldschmidt, Hartmut , Basu, Supratik , Hulin, Cyrille , Weisel, Katja C , Mohty, Mohamad , Leleu, Xavier , Jakubowiak, Andrzej , Cook, Gordon , Quach, Hang , Cavo, M., Carson, Robin

Mayo Clinic

Blood Advances | May 5, 2026 | Volume: 10 | Issue: 13 | Pages: 4541-4550

10.1182/bloodadvances.2025019323 | PMID 42085642 Get It

Abstract Both the phase 3 MAIA and ALCYONE studies demonstrated significant survival benefit with the addition of daratumumab to standard-of-care Rd (Revlimid [lenalidomide] and dexamethasone; D-Rd) or to VMP (Velcade [bortezomib], melphalan, and prednisone; D-VMP), respectively, vs Rd or VMP alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Patients with NDMM are highly susceptible to infection; therefore, gaining a greater understanding of infection incidence may help to mitigate future risk. We conducted a pooled analysis of infection incidence, timing, and management strategies from MAIA and ALCYONE. The median (range) age of the pooled population was 72 (40-93) years. Incidence was higher with D-Rd/D-VMP vs Rd/VMP for grade 3/4 (36.9% vs 22.4%) and grade 5 (3.0% vs 1.5%) infections; however, exposure-adjusted incidence rates were generally comparable between groups. Any-grade infections led to the discontinuation of study treatment in ∼2% of patients across treatment groups. Of the timing intervals explored, the highest incidence of grade 3/4 infection occurred within the first 6-month interval of study treatment initiation in both groups. Median time to the first onset of grade 3/4 infections (per Kaplan-Meier estimates) was 83.3 months and not estimable in the D-Rd/D-VMP and Rd/VMP groups, respectively. Although the rates of D-Rd/D-VMP treatment discontinuation due to infection remained low in MAIA and ALCYONE, clinicians should remain vigilant about infections throughout treatment and follow local guidelines and International Myeloma Working Group recommendations to minimize the risk of infection. These trials were registered at www.ClinicalTrials.gov as NCT02252172 (MAIA) and NCT02195479 (ALCYONE).